NEULAND LABORATORIES
|
The Current P/E Ratio of NEULAND LABORATORIES is 117.32.
Share Price | ₹16,143.6 | Sep 17,2025 |
Market Cap | ₹20,663.8 Cr | |
Earnings-TTM | ₹176.1 Cr | TTM-Consolidated Results |
Price/Earnings | 117.32x | Calculated as Market Cap/Earnings |
---|---|---|
Explore Stock Analytics |
Definition & Calculation of PE (Price/Earnings) ratio of NEULAND LABORATORIES
P/E =
Market Capitalization
/ Net Income
or, using per-share numbers:
P/E = Stock Price /
Earnings Per Share (EPS)
Current Market Cap [ ₹20,663.8 Cr] as on Sep 17,2025
(/) Earnings [ ₹176.1 Cr] based on TTM-Consolidated Results
(=) P/E Ratio [ 117.32x ]
Thus, for NEULAND LABORATORIES , the investors are currently willing to pay 117.32 times earnings to own 1 share of the company.
PE Multiples are the most widely used valuation multiple in practice.
Since P/E ratio uses Net Income in the calculation, P/E multiples are not always reliable for valuing companies with negative earnings.
In such cases, you may consider using Price to Book ratio or Price to Sales ratio of NEULAND LABORATORIES !
P/E ratios, also, would not adjust for differences in the capital structure between companies.
The chart below summarizes the trend in P/E Ratio of NEULAND LABORATORIES over the last five years.
Historical PE (Price/Earnings) ratio chart of NEULAND LABORATORIES
PE Ratio Performance Analysis for NEULAND LABORATORIES
- NEULAND LABORATORIES 's p/e ratio for fiscal years ending Mar2025 to Mar2021 averaged 30.88x.
- NEULAND LABORATORIES 's operated at median p/e ratio of 26.86x from fiscal years ending March 2018 to 2022.
- Looking back at the last 5 fiscal years, NEULAND LABORATORIES 's p/e ratio peaked in Mar2025 at 59.57x.
- NEULAND LABORATORIES 's p/e ratio hit its five-year low in Mar2023 of 14.12x.
How does NEULAND LABORATORIES 's P/E Ratio benchmark against top 10 peers in Pharmaceuticals & Drugs Industry?
Peer Comparison (Pharmaceuticals & Drugs Industry) | Earnings-TTM (Cr) | PE Ratio | Market Cap |
---|---|---|---|
NEULAND LABORATORIES | 176.13 | 117.32 | 20,663.8 |
SUN PHARMACEUTICAL INDUSTRIES LTD | 10,411.50 | 37.34 | 388,752.0 |
DIVIS LABORATORIES LTD | 2,306.00 | 69.66 | 160,626.0 |
CIPLA LTD | 5,406.81 | 23.29 | 125,951.0 |
TORRENT PHARMACEUTICALS LTD | 2,002.00 | 59.91 | 119,932.0 |
DR REDDYS LABORATORIES LTD | 5,726.70 | 19.11 | 109,414.0 |
MANKIND PHARMA LTD | 1,905.51 | 55.64 | 106,025.0 |
ZYDUS LIFESCIENCES LTD | 4,637.80 | 22.45 | 104,130.0 |
LUPIN LTD | 3,722.18 | 24.92 | 92,773.7 |
AUROBINDO PHARMA LTD | 3,417.93 | 18.63 | 63,670.4 |
ABBOTT INDIA LTD | 1,452.29 | 45.28 | 65,762.9 |
Pharmaceuticals & Drugs Industry Benchmark (Top 10) PE Analysis vs NEULAND LABORATORIES 's P/E Ratio
Top 10 Industry Peers | PE Ratio |
---|---|
Min industry PE | 18.63x |
Max industry PE | 117.32x |
Median industry PE | 37.34x |
Average industry PE | 44.87x |
You may also like the below Video Courses